This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

KLAS Smart Pump/EMR Integration Report Cites CareFusion As A Leader In EMR Interoperability, Alaris® Infusion Devices Receive High Ratings

SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- CareFusion (NYSE: CFN), a leading global medical technology company, today announced that the 2013 Smart Pump/EMR Integration Report from KLAS Research cites CareFusion as the technology leader that is poised to take the lead in integrating smart pumps with electronic medical records (EMR) and the only company that currently has a customer using EMR interoperability with large volume and syringe infusion pumps. In addition, Alaris® System infusion pumps received the highest overall score in the syringe pump and patient-controlled analgesia (PCA) pump categories.

According to the report, 18 hospitals are expected to integrate their EMR and smart pumps by the end of 2014, and 9 of those hospitals have chosen CareFusion's interoperability solution—which is more than twice as many contracts as any other infusion pump vendor. This also marks the second year in a row that CareFusion has received the highest overall score in the syringe and PCA pump categories, and the Alaris® Pump module moved up to take the second place spot in the Large Volume Pump category.

"Providers make it clear they feel smart pump and EMR integration is the future of how IV medications will be administered," said Coray Tate, report author for the Smart Pumps 2013 Report from KLAS. "They see integration as a big step forward in patient safety, one that will one day be the industry standard. The question on everyone's mind is, 'how far away is the future?'"

CareFusion's interoperability solution supports wireless pre-population of infusion parameters onto its large volume and syringe pumps and sending of near real-time infusion status back to the EHR for documentation.

"We are extending our leadership in today's infusion devices to include the next frontier of EMR interoperability," said J.C. Kyrillos, senior vice president and general manager of Infusion for CareFusion. "Using one platform for large volume pumps, syringe pumps and PCA is a key component to our strategy of providing the best and least complicated solution for our hospital customers."

CareFusion has implemented its EMR Interoperability solution at Oklahoma Heart Hospital and Children's Hospitals and Clinics of Minnesota, which is the only children's hospital in the country that has implemented a smart pump/EMR interoperability solution and the only hospital in the country to integrate both large volume and syringe pumps.

"In today's evolving health care landscape, hospitals must effectively integrate health information technology and medical devices into their best practices in order to enhance patient safety and improve clinician workflow," said Bobbie Carroll, senior director of patient safety and informatics at Children's Hospitals and Clinics of Minnesota. "Our smart pump and EMR integration helps us do both of those things, while further securing the health and care of our patients. The integration with our syringe pumps is a critical component to our system that provides increased safety for syringe infusions, which can include high-risk drugs that need to be monitored very closely."

To learn more about the Alaris System and EMR interoperability view videos from Children's Hospital and Clinics of Minnesota and Oklahoma Heart Hospital.

"We know we have better patient safety now," said Steve Miller, chief information officer at Oklahoma Heart Hospital. "In just the first six months of being live with the pumps, our high-risk overrides decreased by 47 percent, reprogrammed infusions decreased by 43 percent, severe harms averted decreased by 23 percent and overall guardrail alerts decreased by 15 percent. We did a six-month check and saw our armband scanning for IVs go up substantially as well, from about 36 percent to about 75 percent. The interoperability has made all of our numbers better."

More information on CareFusion's interoperability solutions can be found at

About CareFusion Corporation

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,834.91 +114.99 0.65%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs